You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
強生(JNJ.US)暫停對新冠疫苗銷售指引 下調利潤預測
格隆匯4月19日丨強生公司(JNJ.N)預計,經調整後的全年獲利預估為每股10.15-10.35美元,低於此前預估的10.40-10.60美元。該公司早些時候曾預計這款產品的銷售額可達35億美元,但由於美國市場需求低迷和安全問題以及生產瓶頸問題,這款產品與競爭對手mRNA疫苗相比表現不佳,並暫停對產品的銷售預測。輝瑞預測,與BioNTech合作開發的新冠疫苗的銷售額將在2022年達到320億美元,Moderna預測為210億美元。去年,其合同製造商Emergent BioSolutions(EBS.US)位於馬里蘭州的工廠因原料意外混合而導致約1500萬劑疫苗毀於一旦,因此被美國FDA勒令停產。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account